Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (15417)	6/23/2001 10:25:33 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

No I do not love TSC. I despise them, and see some of what they are doing as a move to cover their complicity in an attack on XOMA. Xanelim trials wrote up rebound whenever a doctor said that the psoriasis had returned. Amevive trials had no rebound. Why? Only hospitalization was considered rebound!!! Listen to the call. You must be putting me on, just to get me to keep explaining why Amevive is such a disaster. Just can't believe you heard the BGEN call and still feel so comfortable. It came after the market close so if you really belive the decline was due to Serrano and Avonex then watch out Monday. IMO the news leaked, see the N.Y. Times article which was pre call. This would be better for BGEN holders since some of the pressure may be off. There is no doubt in my mind that institutions will continue dumping BGEN. Almost every fund that makes group decisions will now have those that opposed buying BGEN insisting it be dumped, and using the purchase against their peers, if they are trying to shaft them.